0.00Open130.20Pre Close0 Volume1 Open Interest140.00Strike Price0.00Turnover102.66%IV7.58%PremiumDec 20, 2024Expiry Date111.17Intrinsic Value100Multiplier24DDays to Expiry19.04Extrinsic Value100Contract SizeAmericanOptions Type0.9912Delta0.0004Gamma2.25Leverage Ratio-0.0479Theta0.0908Rho2.23Eff Leverage0.0155Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet